Postmarketing Vaccine Safety Assessments

After the initial randomized clinical trials and emergency use authorization of the COVID-19 vaccines by the US Food and Drug Administration (FDA) during the COVID-19 pandemic, the US Centers for Disease Control and Prevention (CDC) and the FDA undertook extensive postmarketing vaccine safety surveillance activities in the US, with close monitoring by an independent safety committee. Analysis of surveillance data identified several important adverse events associated with receipt of the COVID-19 vaccines.
Source: JAMA - Category: General Medicine Source Type: research